Patents by Inventor Thomas Dock Steenstrup
Thomas Dock Steenstrup has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9982033Abstract: The invention relates to a method for the production of a Factor VIII polypeptide, the method comprising the steps of a) culturing a mammalian cell expressing a Factor VIII polypeptide under conditions for expression of said Factor VIII polypeptide, said culturing conditions involving a cell culture medium comprising a C2-domain ligand, and b) isolating the expressed Factor VIII polypeptide from the mammalian cell by suitable means.Type: GrantFiled: April 30, 2008Date of Patent: May 29, 2018Assignee: Novo Nordisk A/SInventors: Laust Bruun Johnsen, Ida Hilden, Gert Bolt, Thomas Dock Steenstrup
-
Publication number: 20160222086Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half-life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.Type: ApplicationFiled: August 20, 2015Publication date: August 4, 2016Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn Defrees
-
Patent number: 9150848Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.Type: GrantFiled: May 8, 2014Date of Patent: October 6, 2015Assignee: Novo Nordisk A/sInventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn DeFrees
-
Patent number: 8940504Abstract: The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.Type: GrantFiled: March 13, 2012Date of Patent: January 27, 2015Assignee: Novo Nordisk Healthcare AGInventors: Thomas Dock Steenstrup, Peder Lisby Norby
-
Publication number: 20140242057Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.Type: ApplicationFiled: May 8, 2014Publication date: August 28, 2014Applicant: Novo Nordisk A/SInventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn DeFrees
-
Patent number: 8536126Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.Type: GrantFiled: February 5, 2013Date of Patent: September 17, 2013Assignee: Novo Nordisk A/SInventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn DeFrees
-
Publication number: 20130189239Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.Type: ApplicationFiled: February 26, 2009Publication date: July 25, 2013Applicant: Novo Nordisk A/SInventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn Defrees
-
Publication number: 20120171721Abstract: The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.Type: ApplicationFiled: March 13, 2012Publication date: July 5, 2012Applicant: Novo Nordisk Health Care AGInventors: Thomas Dock Steenstrup, Peder Lisby Norby
-
Patent number: 8158771Abstract: The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.Type: GrantFiled: February 4, 2010Date of Patent: April 17, 2012Assignee: Novo Nordisk Health Care AGInventors: Thomas Dock Steenstrup, Peder Lisby Norby
-
Publication number: 20100137570Abstract: The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.Type: ApplicationFiled: February 4, 2010Publication date: June 3, 2010Applicant: Novo Nordisk Health Care AGInventors: Thomas Dock Steenstrup, Peder Lisby Norby
-
Publication number: 20100120094Abstract: The invention relates to a method for the production of a Factor VIII polypeptide, the method comprising the steps of a) culturing a mammalian cell expressing a Factor VIII polypeptide under conditions for expression of said Factor VIII polypeptide, said culturing conditions involving a cell culture medium comprising a C2-domain ligand, and b) isolating the expressed Factor VIII polypeptide from the mammalian cell by suitable means.Type: ApplicationFiled: April 30, 2008Publication date: May 13, 2010Applicant: NOVO NORDISK A/SInventors: Laust Bruun Johnsen, Ida Hilden, Gert Bolt, Thomas Dock Steenstrup
-
Patent number: 7696318Abstract: The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.Type: GrantFiled: July 13, 2006Date of Patent: April 13, 2010Assignee: Novo Nordisk Health Care AGInventors: Thomas Dock Steenstrup, Peder Lisby Norby
-
Publication number: 20090252720Abstract: The invention is related to FIX analogues which have an increased circulation time in the blood stream before activation compared to that that of native FIX (and a week after injection to a patient retains at least about 5% of the FIX activity compared to the initial activity peak value reached after injection). The claimed FIX analogues comprise an inserted cysteine residue which has been further modified by conjugation with a chemical group increasing the molecular weight of the FIX analogue.Type: ApplicationFiled: May 24, 2007Publication date: October 8, 2009Applicant: Novo Nordisk Health Care AGInventors: Henrik Ostergaard, Ole Hvilsted Olsen, Henning Ralf Stennicke, Thomas Dock Steenstrup
-
Publication number: 20090100533Abstract: The present invention relates to a novel method for preparing gamma-carboxylated poly-peptides, including coagulation Factors VII, IX, X and Protein C. The present invention also relates to novel host cells and recombinant vectors to be used in this improved method for preparing gamma-carboxylated polypeptides.Type: ApplicationFiled: December 19, 2005Publication date: April 16, 2009Applicant: Novo Nordisk Health Care AGInventor: Thomas Dock Steenstrup
-
Publication number: 20080299611Abstract: The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.Type: ApplicationFiled: July 13, 2006Publication date: December 4, 2008Applicant: Novo Nordisk Health Care AGInventors: Thomas Dock Steenstrup, Peder Lisby Norby
-
Publication number: 20080227691Abstract: The invention is related to a FVIII analogue which has a circulation time in the blood stream before activation of at least about two times of that of native FVIII and a week after injection to a patient retains at least about 5% of the FVIII activity compared to the initial activity peak value reached after injection. The claimed FVIII analogues comprise a targeted disruption of one or more of the clearance sites in the FVIII molecule by introduction of at least one N-glycosylation site or by introduction of at least one Cys residue within or spatially close to the clearance site in the A2 domain or a combination thereof. The inserted cysteine residues may be further modified by conjugation with a chemical group increasing the molecular weight of the FVIII analogue.Type: ApplicationFiled: April 3, 2006Publication date: September 18, 2008Applicant: Novo Nordisk Health Care AGInventors: Henrik Ostergaard, Gert Bolt, Thomas Dock Steenstrup
-
Publication number: 20040110929Abstract: The present invention relates to novel compounds that bind to and inhibit the activity of tissue factor (TF) and mediate a cytolytic immune response.Type: ApplicationFiled: July 11, 2003Publication date: June 10, 2004Inventors: Soren E. Bjorn, Else Marie Nicolaisen, Thomas Dock Steenstrup